

**FMHL/SEC/SE/BM/JULY'18**

**JULY 31, 2018**

The General Manager  
Department of Corporate Services  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

**Scrip Code: 523696**

**Sub: Outcome of the Board Meeting**

Dear Sir,

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. July 31, 2018, *inter-alia*, considered and approved the following: -

1. Un-audited Financial Results of the Company for the quarter ended on June 30, 2018 along with Limited Review Report thereon;
2. Recommendation for appointment of Mr. Daljit Singh - Non- Executive Director (DIN: 00135414), who is liable to retire by rotation at the ensuing Annual General Meeting, subject to the approval of the shareholders;

Further, Mr. Daljit Singh declared that, he is not debarred from accessing the capital markets and / or restrained from holding any position / office of director in a company pursuant to order of SEBI or any other such authority;

3. Regularization of Mr. Rahul Ranjan (DIN: 06953080) as Director of the Company at the ensuing Annual General Meeting.

Further, Mr. Rahul Ranjan declared that, he is not debarred from accessing the capital markets and / or restrained from holding any position / office of director in a company pursuant to order of SEBI or any other such authority;

4. Regularization of Mr. Akshay Kumar Tiwari (DIN: 07930333) as Director of the Company at the ensuing Annual General Meeting.

Further, Mr. Akshay Kumar Tiwari declared that, he is not debarred from accessing the capital markets and / or restrained from holding any position / office of director in a company pursuant to order of SEBI or any other such authority; and

5. Variation of terms of appointment Mr. Meghraj A. Gore, Whole Time Director of the Company in terms of section 197 and Schedule V of the Companies Act, 2013, subject to the shareholders' approval in the ensuing Annual General Meeting;



**Fortis Malar Hospitals**

52, First Main Road, Gandhi Nagar, Adyar,  
Chennai, Tamil Nadu – 600 020

Tel : +91 44 4289 2222

Fax : +91 44 4289 2293

Email : [secretarial.malar@malarhospitals.in](mailto:secretarial.malar@malarhospitals.in)

Website: [www.fortismalar.com](http://www.fortismalar.com)

Please find enclosed 'Un- audited Financial Results' of the Company and 'Limited Review Report' thereon for the quarter ended June 30, 2018 along with a copy of the press release being issued in this regard.

The Board Meeting commenced at 1500 Hours and concluded at 1630 Hours.

This is for your information and records please.

Yours faithfully

For **Fortis Malar Hospitals Limited**

**Shashank Porwal**  
**Company Secretary**  
**M. No. 51957**

**FORTIS MALAR HOSPITALS LIMITED (CIN: L85110PB1989PLC045948)**  
**Regd. Office: Fortis Hospital, Sector 62, Phase - VIII, Mohali-160062**  
**Tel Numbers: 0172 5096001 & Tele Fax No : 0172 5096002**  
**Website: www.fortismalar.com; Email: secretarial.malar@malarhospitals.in**  
**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2018**

(Rs. In Lakhs except EPS)

	Quarter ended		Year ended	
	June 30, 2018	March 31, 2018	June 30, 2017	March 31, 2018
	(Unaudited)	(Audited) (Refer Note 4)	(Unaudited)	(Audited)
<b>1 Income</b>				
a) Revenue from operations	3,356.13	4,037.75	3,384.24	14,919.27
b) Other Income	219.18	223.68	185.33	818.46
<b>Total Income</b>	<b>3,575.31</b>	<b>4,261.43</b>	<b>3,569.57</b>	<b>15,737.73</b>
<b>2 Expenses</b>				
a) Purchase of Medical Consumables and Drugs	764.43	882.39	738.88	3,277.29
b) Changes in Inventories of Medical Consumables and Drugs	3.57	103.71	(81.46)	28.98
c) Employee Benefits Expense	571.73	528.47	538.02	2,154.40
d) Finance Costs	13.58	7.22	11.22	38.47
e) Professional Charges to Doctors	987.14	1,071.20	1,063.72	4,257.85
f) Clinical Establishment Fees	510.86	553.29	502.00	2,120.13
g) Depreciation and Amortization Expenses	107.41	108.44	100.80	421.41
h) Other Expenses	715.71	766.14	728.41	2,908.21
<b>Total Expenses</b>	<b>3,674.43</b>	<b>4,020.86</b>	<b>3,601.59</b>	<b>15,206.74</b>
<b>3 Profit / (Loss) before tax (1-2)</b>	<b>(99.12)</b>	<b>240.57</b>	<b>(32.02)</b>	<b>530.99</b>
<b>4 Tax expense</b>				
- Current Tax	(38.34)	68.19	19.64	262.20
- Deferred Tax	8.91	52.66	(30.33)	(45.33)
<b>Total Tax Expenses</b>	<b>(29.43)</b>	<b>120.85</b>	<b>(10.69)</b>	<b>216.87</b>
<b>5 Net Profit / (Loss) After Tax (3-4)</b>	<b>(69.69)</b>	<b>119.72</b>	<b>(21.33)</b>	<b>314.12</b>
<b>6 Other Comprehensive Income / (Loss) ( Net of Tax)</b>	<b>12.38</b>	<b>2.65</b>	<b>(4.76)</b>	<b>12.30</b>
<b>7 Total Comprehensive Income / (Loss) for the period (5+6)</b>	<b>(57.31)</b>	<b>122.37</b>	<b>(26.09)</b>	<b>326.42</b>
8 Paid up Equity Share Capital (Face Value Rs.10 each)	1,869.95	1,869.95	1,869.95	1,869.95
9 Other Equity				8,289.62
<b>10 Earnings Per Share (EPS) based on (5) above (of Rs. 10 each) - (Not annualised in the quarters)</b>				
- Basic	(0.37)	0.64	(0.11)	1.68
- Diluted	(0.37)	0.64	(0.11)	1.67

**Notes**

1 The above unaudited standalone financial results have been reviewed by the Audit and Risk Management Committee, approved and taken on record by the Board of Directors in their respective meetings held on July 31, 2018. The Statutory auditors have carried out a limited review of these results.

2 The Company operates in a single segment (i.e.) Healthcare Services and hence does not have any additional disclosures to be made under IND AS 108 - Operating Segments.

3 The Board of directors of the Company have approved the withdrawal of "the composite scheme of Arrangement and Amalgamation" (the Scheme) between the Company, Fortis Healthcare Limited and SRL Limited on June 13, 2018 and subsequently the Company obtained necessary approval from the National Company Law Tribunal for withdrawal of the Scheme on June 15, 2018.

4 Figures for the quarter ended March 31, 2018 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter for the financial year 2017-18.



By Order of the Board  
For and on behalf of Board of Directors

*[Signature]*  
D. Singh  
Director  
DIN No.00135414

Place: Chennai  
Date: July 31, 2018

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF FORTIS MALAR HOSPITALS LIMITED**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **FORTIS MALAR HOSPITALS LIMITED** ("the Company"), for the Quarter ended June 30, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins & Sells LLP**  
Chartered Accountants  
(Firm Registration No. 117366W/W-100018)



*Geetha Suryanarayanan*  
**Geetha Suryanarayanan**  
Partner

(Membership No. 29519)

Chennai, July 31, 2018

### **FORTIS MALAR REPORTS Q1FY19 REVENUE AT RS 33.56 CR**

### **OPERATING PROFIT FOR THE QUARTER AT RS(-)1.97 CR**

**Chennai, July 31, 2018:** Fortis Malar Hospitals Limited, a subsidiary of Fortis Healthcare Limited, a leading integrated healthcare delivery provider in India, today announced its results for the quarter ended June 30, 2018.

**Commenting on the results Mr. Daljit Singh, Chairman, Fortis Malar Hospitals Limited, said,** “Fortis Malar has been doing exceptional clinical work and has achieved the unique distinction of conducting around 250 Heart transplants, reinforcing its position as a world class super specialty tertiary care centre. Additionally, it has made a mark for itself by performing complex and high end surgeries particularly in Cardiology, Neurology, Mother and Child Care, among others. I am delighted with the great work being done by our team of doctors, nurses, paramedics and other staff members and am confident that we will continue to deliver world class clinical programs, with consistently superior results in the future, as well.”

#### **Financial Highlights for the Quarter (Q1FY19)**

- Fortis Malar Hospitals reported operating revenue of Rs 33.56 Cr compared to Rs 33.84 Cr reported in the corresponding quarter of the previous year.
- Operating profit for the quarter stood at Rs (-) 1.97 Cr compared to Rs (-) 1.05 Cr in the corresponding quarter of previous year.
- Profit before tax stood at Rs.(-)0.99 Cr compared to Rs. (-)0.32 Cr in corresponding quarter of previous year.
- Net profit for the quarter was at Rs (-) 0.70 Cr compared to Rs. (-) 0.21 Cr in corresponding quarter of previous year.
- During the quarter, Fortis Malar witnessed growth in its key specialties such as Orthopedics, Cardiology, Pulmonology, which grew by 37%, 21% & 16% respectively, compared to the corresponding quarter of previous year.

## **Fortis Malar Hospital achieves significant milestone by completing 200 Bilateral Knee Replacement Surgeries**

Fortis Malar holds the record of conducting knee replacement surgeries in less than 45 minutes with 99 percent success rate and less than 1 percent revision rate. Fortis Malar did the successful completion of 200 bilateral knee replacement surgeries. This significant clinical feat was achieved by **Dr. A B Govindaraj, Chief Consultant Orthopedic & Joint Replacement Surgeon** and his team of doctors at Fortis Malar Hospital. Over the past four years, Fortis Malar successfully completed more than 400 knee replacement surgeries in more than 200 patients with 99% success rate. This milestone highlights the uniqueness of the hospital to offer end to end solutions under one roof.

## **Acclaimed Tamil Actress Aditi Balan honours Blood Donors at Fortis Malar Hospital**

On World Blood Donor day, **Fortis Malar Hospital** recognized and honored voluntary, unpaid blood donors for their life saving gift at an event held at the hospital auditorium. Noted and critically acclaimed Tamil actor Aditi Balan graced the occasion and felicitated the blood donors with special mementos for their yeoman service. Speaking about this initiative **Dr Jyotsna Codaty, HOD, Transfusion Medicine, Fortis Malar Hospital, Chennai** said, “The amazing fact about donating blood is that a single donation can save up to three lives, because we can receive different blood samples from a single donor and it can thereby accordingly be transferred to other patients”

## **Fortis Malar Hospital and Round Table & Ladies Circle India successfully completes 100 free surgeries**

New beginning for underprivileged children suffering from cardiac ailments through ‘Heart to Heart’ initiative. **Fortis Malar Hospital** in association with **Round Table India** - Madras Mylapore Round Table 3 (MMRT 3), Madras Anchorage Round Table 100 (MART 100), Madras Mylapore Ladies Circle 4 (MMLC 4) completed 100 free surgeries to treat children from underprivileged section of the society under their Heart to Heart project. The initiative was started in September 2017 and will continue to treat deserving children with congenital heart disease.

## **Fortis Malar Hospital educates 'to be' and 'new dads' this Father's Day on breastfeeding practices**

**Fortis Malar Hospital** conducted a special session on breastfeeding and lactation for 'to be' and 'new dads' to mark World Father's Day. The program saw **Dr Jayashree Jayakrishnan, Lactation Consultant, Fortis Malar** sharing her insights on being a labour coach and ways to support

successful breastfeeding practices. The session predominantly concentrated on “How fathers can prepare themselves to be a labour coach for mothers” and “How a father can be a Breastfeeding Advocate.” The parents were further given insights on Kangaroo care, a method of caring for a premature baby in which the infant is held in skin-to-skin contact by a parent, typically the mother for as long as possible each day till normalcy.

### **Corporate Social Responsibility**

Playing its part as a good corporate citizen, Fortis Malar has been involved in activities that momentarily contribute to society. The following CSR activities were undertaken during the quarter:

### **Critically ill School Topper from Bihar receives free Heart Transplant at Fortis Malar Hospital**

15-year-old girl belonging to underprivileged section of society received financial aid from Aishwarya Trust. Daughter of a tailor & domestic help, she is keen to re-join school soon. The team of doctors at **Fortis Malar Hospital** performed a successful heart transplant surgery on the girl. The patient topped her school before she was diagnosed with Dilated Cardiomyopathy. She received the donor heart during a surgery that lasted less than 4 hours. The team of doctors who successfully performed this surgery was led by **Dr K R Balakrishnan, Director, Cardiac Sciences, Fortis Malar Hospital** and **Dr Suresh Rao KG, Head of the Department, Critical Care and Cardiac Anaesthesia, Fortis Malar Hospital**.

### **Doctors from Fortis Malar and Therukoothu Artists come together to fight Substance Abuse.**

Doctors of **Fortis Malar Hospital** and Therukoothu artists came together to create awareness about evils of substance abuse at **Trustway Foundation – De-Addiction and Rehabilitation centre**. The informative awareness session was attended by 120 people who were made aware about ill effects of drug abuse as well as abusive alcohol consumption. The session was conducted by **Dr P Basumani, Consultant, Medical Gastroenterologist at Fortis Malar Hospital**. Therukoothu is a local art form comprising of storytelling, dialogue rendering, songs and dance. It was used to touch upon alcoholism and its related issues. The performance was intertwined with people’s emotions, values and attitudes to life, in such a way that the story being narrated became the expression of addicts and their dreaded experiences with alcohol.

### **About Fortis Malar Hospitals Ltd**

Fortis Malar Hospital (formerly known as Malar Hospital) was acquired by Fortis Healthcare (India) Limited in early 2008. The hospital founded in 1992, is established as one of the largest corporate hospitals in Chennai providing

quality super specialty and multi-specialty healthcare services. Fortis Malar Hospitals, with 180 beds, focuses on providing comprehensive medical care in the areas of Cardiology and Cardiac Surgery, Neuro Surgery, Gynaecology, Orthopaedics, Gastroenterology, Neurology, Paediatrics, Diabetics, Nephrology and Internal Medicine.

Fortis Malar Hospital has a state of the art Cath Lab and multiple dedicated cardiac operation theatres and intensive coronary care units. Several rare and complex Adult and Paediatric Cardiac surgeries, Orthopedic and Joint replacements, Neurosurgeries and Plastic reconstruction surgeries have been performed at this hospital. The hospital's Obstetrics and Gynaecology services are among the busiest in the city, successfully performing many complicated deliveries and surgeries. They are supported by a dedicated Neonatology unit.

### **About Fortis Healthcare Ltd**

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Dubai, Mauritius and Sri Lanka with 45 healthcare facilities (including projects under development), approximately 10,000 potential beds and over 370 diagnostic centers.

### **DISCLAIMER**

*This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.*

### **FOR MORE INFORMATION PLEASE CONTACT**

**Rajarishi**  
PR & Communications  
Fortis Malar Hospitals Ltd  
Mobile: 9841361018  
[rajarishi.r@fortishealthcare.com](mailto:rajarishi.r@fortishealthcare.com)